Product logins

Find logins to all Clarivate products below.


Bispecific Therapies – Special Topics – Special Topics: Bispecific Therapies (G7 and China)

Bispecific therapies represent a class of drug with two binding sites directed at two different antigens or epitopes. This dual action makes bispecific therapies a promising approach to improve target specificity. These therapies can be designed to recruit and activate immune cells, interfere with receptor signaling, and inactivate signaling ligand. Drug manufacturers are extensively exploring bispecific therapies either as monotherapy or in combination with other targeted immunotherapies. To date, six bispecific therapies have been approved across the G7 and China, for both hematological malignancies and solid tumors. This Special Topics report provides a comprehensive view of the current bispecific therapy landscape and pipeline, with coverage of therapies in early-phase through late-phase development across a range of oncology indications.

QUESTIONS ANSWERED

  • What is the current landscape for approved bispecific therapies? What are the key trends? What impact will these treatments have in their respective oncology indications?
  • What does the bispecific therapy pipeline look like by phase of development? What are the key classes of therapies? What are the key developers? In which geographies is development focused?
  • What are the trends in the development of bispecific therapies? In which oncology indications most bispecific therapies are being investigated? What are the key targets in solid and hematological tumors?

GEOGRAPHIES

United States, EU5, Japan, and China

PRIMARY AND SECONDARY MARKET RESEARCH

In-depth interviews with six key opinion leaders (hematologist-oncologists); analysis of industry and company reports; peer-reviewed journals; pipeline databases (Cortellis, ClinicalTrials.gov); industry / scientific conferences; news; media

KEY DRUGS COVERED

Blincyto, Kadulini, Kimmtrak, Lunsumio, Rybrevant, and Tecvayli

EMERGING THERAPIES

Therapies in Phase III development (e.g., glofitamab, elranatamab, epcoritamab)

PRODUCT DESCRIPTION

Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive pipeline analysis of the bispecific therapy landscape in relevant oncology indications.

Related Market Assessment Reports

Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…